Prevention of the Postthrombotic Syndrome: Where Do We Stand?

Abstract

The postthrombotic syndrome (PTS) is a common complication of lower extremity deep vein thrombosis (DVT) that impairs patients' health-related quality of life despite the use of standard therapy. Prevention of PTS is an important goal of quality DVT care, and includes prevention of recurrent DVT with anticoagulation, use of compression therapy, mitigation of functional contributors to limb edema, use of endovascular therapy to prevent venous obstruction and valvular reflux, and reduction of inflammation within the involved veins and limb. This study reviews best practices in clinical PTS prevention, clinical trial evidence on endovascular therapy outcomes, and mechanistic observations about PTS with the goal of preparing the interventional radiology physician to deliver outstanding patient care and to lead local and national multi-specialty initiatives that are aimed at PTS prevention.

Keywords

deep vein thrombosis - postthrombotic syndrome - thrombolysis - thrombectomy - pharmaco-mechanical - interventional radiology

Publikationsverlauf

Artikel online veröffentlicht:
26. September 2025

• References

• 1 Kahn SR, Shrier I, Julian JA. et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149 (10) 698-707
• 2 Kahn SR, Shapiro S, Wells PS. et al; SOX trial investigators. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383 (9920) 880-888
• 3 Enden T, Haig Y, Kløw NE. et al; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379 (9810) 31-38
• 4 Vedantham S, Goldhaber SZ, Julian JA. et al; ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017; 377 (23) 2240-2252
• 5 Notten P, Ten Cate-Hoek AJ, Arnoldussen CWKP. et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol 2020; 7 (01) e40-e49
• 6 Kahn SR, Shbaklo H, Lamping DL. et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 2008; 6 (07) 1105-1112
• 7 Kahn SR, Ducruet T, Lamping DL. et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med 2005; 165 (10) 1173-1178
• 8 Meissner MH, Manzo RA, Bergelin RO, Markel A, Strandness Jr DE. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg 1993; 18 (04) 596-605 , discussion 606–608
• 9 Meissner MH, Caps MT, Bergelin RO, Manzo RA, Strandness Jr DE. Propagation, rethrombosis and new thrombus formation after acute deep venous thrombosis. J Vasc Surg 1995; 22 (05) 558-567
• 10 Semba CP, Dake MD. Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis. Radiology 1994; 191 (02) 487-494
• 11 Kahn SR. Measurement properties of the Villalta scale to define and classify the severity of the post-thrombotic syndrome. J Thromb Haemost 2009; 7 (05) 884-888
• 12 Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost 2009; 7 (05) 879-883
• 13 Rutherford RB, Padberg Jr FT, Comerota AJ, Kistner RL, Meissner MH, Moneta GL. Venous severity scoring: an adjunct to venous outcome assessment. J Vasc Surg 2000; 31 (06) 1307-1312
• 14 Vasquez MA, Rabe E, McLafferty RB. et al; American Venous Forum Ad Hoc Outcomes Working Group. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg 2010; 52 (05) 1387-1396
• 15 Kahn SR, Comerota AJ, Cushman M. et al; American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 2014; 130 (18) 1636-1661
• 16 Vedantham S, Gloviczki P, Carman TL. et al. Delphi consensus on reporting standards in clinical studies for endovascular treatment of acute iliofemoral venous thrombosis and chronic iliofemoral venous obstruction. Circ Cardiovasc Interv 2023; 16 (07) e012894
• 17 Stevens SM, Woller SC, Kreuziger LB. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report – executive summary. Chest 2021; 160 (06) 2247-2259
• 18 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
• 19 Prandoni P, Lensing AW, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125 (01) 1-7
• 20 Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?. Am J Med 2001; 110 (07) 515-519
• 21 Shao J, Zhou Q, Jin F. et al. A systematic review and Bayesian network meta-analysis on the effect of different anticoagulants on the prophylaxis of post-thrombotic syndrome after deep venous thrombosis. J Clin Med 2023; 12 (23) 7450
• 22 de Athayde Soares R, Matielo MF, Brochado Neto FC, Nogueira MP, Almeida RD, Sacilotto R. Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery 2019; 166 (06) 1076-1083
• 23 Wik HS, Kahn SR, Eriksson H. et al. Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: a long-term cross-sectional follow-up of RE-COVER study patients. J Thromb Haemost 2021; 19 (10) 2495-2503
• 24 Partsch H, Kaulich M, Mayer W. Immediate mobilisation in acute vein thrombosis reduces post-thrombotic syndrome. Int Angiol 2004; 23 (03) 206-212
• 25 Brandjes DP, Büller HR, Heijboer H. et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349 (9054) 759-762
• 26 Prandoni P, Lensing AW, Prins MH. et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141 (04) 249-256
• 27 Meng J, Liu W, Wu Y, Xiao Y, Tang H, Gao S. Is it necessary to wear compression stockings and how long should they be worn for preventing post thrombotic syndrome? A meta-analysis of randomized controlled trials. Thromb Res 2023; 225: 79-86
• 28 Palacios FS, Rathbun SW. Medical treatment for postthrombotic syndrome. Semin Intervent Radiol 2017; 34 (01) 61-67
• 29 Fukaya E, Kolluri R. Nonsurgical management of chronic venous insufficiency. N Engl J Med 2024; 391 (24) 2350-2359
• 30 Kahn SR, Shrier I, Shapiro S. et al. Six-month exercise training program to treat post-thrombotic syndrome: a randomized controlled two-centre trial. CMAJ 2011; 183 (01) 37-44
• 31 Padberg Jr FT, Johnston MV, Sisto SA. Structured exercise improves calf muscle pump function in chronic venous insufficiency: a randomized trial. J Vasc Surg 2004; 39 (01) 79-87
• 32 Rook B, van Rijn MJE, Jansma EP, van Montfrans C. Effect of exercise after a deep venous thrombosis: a systematic review. J Eur Acad Dermatol Venereol 2024; 38 (02) 289-301
• 33 Vedantham S, Goldhaber SZ, Kahn SR. et al. Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis. Am Heart J 2013; 165 (04) 523-530.e3
• 34 Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N, Haughton SH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999; 211 (01) 39-49
• 35 Comerota AJ, Kearon C, Gu CS. et al; ATTRACT Trial Investigators. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis: analysis from a stratified multicenter randomized trial. Circulation 2019; 139 (09) 1162-1173
• 36 Kearon C, Gu CS, Julian JA. et al. Pharmacomechanical catheter-directed thrombolysis for acute femoral-popliteal deep-vein thrombosis: analysis from a stratified randomized trial. Thromb Haemost 2019; 119 (04) 633-644
• 37 Weinberg I, Vedantham S, Salter A. et al; ATTRACT Trial Investigators. Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT multicenter randomized trial. Vasc Med 2019; 24 (05) 442-451
• 38 Magnuson EA, Chinnakondepalli K, Vilain K. et al. Cost-effectiveness of pharmacomechanical catheter-directed thrombolysis vs. standard anticoagulation in patients with proximal deep-vein thrombosis: results from the ATTRACT Trial. Circ Cardiovasc Qual Outcomes 2019; 12 (10) e005659
• 39 Kahn SR, Julian JA, Kearon C. et al; ATTRACT Trial Investigators. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 2020; 8 (01) 8-23.e18
• 40 Rabinovich A, Gu CS, Vedantham S. et al; ATTRACT Trial Investigators. External validation of the SOX-PTS score in a prospective multicenter trial of patients with proximal deep vein thrombosis. J Thromb Haemost 2020; 18 (06) 1381-1389
• 41 Razavi MK, Salter A, Goldhaber SZ. et al. Correlation between post-procedure residual thrombus and clinical outcome in deep vein thrombosis patients receiving pharmacomechanical thrombolysis in a multi-center randomized trial. J Vasc Interv Radiol 2020; 31 (10) 1517-1528.e2
• 42 Lee A, Gu CS, Vedantham S, Kearon C, Blostein M, Kahn SR. Performance of two clinical scales to assess quality of life in patients with post-thrombotic syndrome. J Vasc Surg Venous Lymphat Disord 2021; 9 (05) 1257-1265.e2
• 43 Vedantham S, Salter A, Lancia S, Lewis L, Thukral S, Kahn SR. Clinical outcomes of a pharmacomechanical catheter-directed venous thrombolysis strategy that included rheolytic thrombectomy in a multicenter randomized trial. J Vasc Interv Radiol 2021; 32 (09) 1296-1309.e7
• 44 Goldhaber SZ, Magnuson EA, Chinnakondepalli KM, Cohen DJ, Vedantham S. Catheter-directed thrombolysis for deep vein thrombosis: 2021 update. Vasc Med 2021; 26 (06) 662-669
• 45 Thukral S, Salter A, Lancia S, Kahn SR, Vedantham S. Predictors of clinical outcomes of pharmacomechanical catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis: analysis of a multicenter randomized trial. J Vasc Interv Radiol 2022; 33 (10) 1161-1170.e11
• 46 Rinfret F, Gu CS, Vedantham S, Kahn SR. New and known predictors of the postthrombotic syndrome: a subanalysis of the ATTRACT trial. Res Pract Thromb Haemost 2022; 6 (06) e12796
• 47 Pop CT, Gu CS, Vedantham S, Galanaud JP, Kahn SR. Exploring the Villalta scale to capture postthrombotic syndrome using alternative approaches: a subanalysis of the ATTRACT trial. Res Pract Thromb Haemost 2022; 7 (01) 100032
• 48 Shih J, Gu C, Vedantham S, Kaufman J, Kahn SR. Impact of self-reported race on Villalta scale post-thrombotic syndrome scores and correlation with venous disease-specific quality of life: an exploratory analysis of the ATTRACT Trial. Res Pract Thromb Haemost 2024; 8 (08) 102609
• 49 Haig Y, Enden T, Grøtta O. et al; CaVenT Study Group. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol 2016; 3 (02) e64-e71
• 50 Notten P, de Smet AAEA, Tick LW. et al. CAVA (ultrasound-accelerated catheter-directed thrombolysis on preventing post-thrombotic syndrome) trial: long-term follow-up results. J Am Heart Assoc 2021; 10 (11) e018973
• 51 Enden T, Wik HS, Kvam AK, Haig Y, Kløw NE, Sandset PM. Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. BMJ Open 2013; 3 (08) e002984
• 52 Vedantham S, Desai KR, Weinberg I. et al. Society of Interventional Radiology Position Statement on the management of acute iliofemoral deep vein thrombosis. J Vasc Interv Radiol 2023; 34 (02) 284-299.e7
• 53 Kakkos SK, Gohel M, Baekgaard N. et al; Esvs Guidelines Committee. Editor's choice - European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 2021; 61 (01) 9-82
• 54 Engelberger RP, Spirk D, Willenberg T. et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis. Circ Cardiovasc Interv 2015; 8 (01) e002027
• 55 Engelberger RP, Stuck A, Spirk D. et al. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis: 1-year follow-up data of a randomized-controlled trial. J Thromb Haemost 2017; 15 (07) 1351-1360
• 56 Haig Y, Enden T, Slagsvold CE, Sandvik L, Sandset PM, Kløw NE. Residual rates of reflux and obstruction and their correlation to post-thrombotic syndrome in a randomized study on catheter-directed thrombolysis for deep vein thrombosis. J Vasc Surg Venous Lymphat Disord 2014; 2 (02) 123-130
• 57 Dexter D, Kado H, Shaikh A. et al. Safety and effectiveness of mechanical thrombectomy from the fully enrolled multicenter, prospective CLOUT registry. J Soc Cardiovasc Angiogr Interv 2023; 2 (02) 100585
• 58 Abramowitz S, Bunte MC, Maldonado TS. et al; CLOUT study collaborators. Mechanical thrombectomy versus pharmacomechanical catheter-directed thrombolysis for the treatment of iliofemoral deep vein thrombosis: a propensity score matched exploratory analysis of 12 month clinical outcomes. Eur J Vasc Endovasc Surg 2024; 67 (04) 644-652
• 59 Jiang K, Li XQ, Sang HF, Qian AM, Rong JJ, Li CL. Mid-term outcome of endovascular treatment for acute lower extremity deep venous thrombosis. Phlebology 2017; 32 (03) 200-206
• 60 Li KX, Diendéré G, Galanaud JP, Mahjoub N, Kahn SR. Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: a narrative review. Res Pract Thromb Haemost 2021; 5 (04) e12527
• 61 Lobastov K, Schastlivtsev I, Barinov V. Use of micronized purified flavonoid fraction together with rivaroxaban improves clinical and ultrasound outcomes in femoropopliteal venous thrombosis: results of a pilot clinical trial. Adv Ther 2019; 36 (01) 72-85
• 62 Schastlivtsev I, Lobastov K, Barinov V, Kanzafarova I. Diosmin 600 in adjunction to rivaroxaban reduces the risk of post-thrombotic syndrome after femoropopliteal deep vein thrombosis: results of the RIDILOTT DVT study. Int Angiol 2020; 39 (05) 361-371
• 63 San Norberto EM, Gastambide MV, Taylor JH, García-Saiz I, Vaquero C. Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis. Vasa 2016; 45 (02) 133-140
• 64 Pishgahi M, Ghane Fard S, Lak Tabriz R, Karimi Toudeshki K, Talebi Z. The effects of 3-month rosuvastatin adjuvant therapy on post thrombotic syndrome following deep vein thrombosis: a randomized clinical trial. Arch Acad Emerg Med 2023; 11 (01) e43
• 65 Delluc A, Ghanima W, Kovacs MJ. et al. Prevention of post-thrombotic syndrome with rosuvastatin: a multicenter randomized controlled pilot trial (SAVER). Thromb Res 2022; 213: 119-124